Bio-Rad is filing fewer patents year after year, which suggests that it is struggling to innovate and develop new products and services. The company is lagging its peers with a negative ROE, and net ...

Bio-Rad Laboratories (NYSE:BIO) is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement. Analysts estimate that Bio-Rad ...

Bio-Rad Laboratories is buying back a considerable amount of its own stock given the shares' current valuation and growth prospects. Profits and sales are expected to rebound in FY2025. A fuller look ...

Bio-Rad Laboratories (BIO) has seen its stock edge upward over the past week, catching some attention among investors. Shares closed at $297.95, reflecting modest gains that contrast with longer-term ...